Target intelligence / Profile preview

Ras-related protein Ral (Ral GTPase (RalA, RalB))

Target
Ral GTPase (RalA, RalB)
Molecular classification
Small GTPase, Enzyme (GTPase), Ras superfamily, Molecular switch
01

Overview

Ras-related protein Ral (Ral GTPase) belongs to the Ras superfamily of small GTPases and functions as a molecular switch, cycling between active GTP-bound and inactive GDP-bound states. It is activated by RalGEFs and inactivated by GTPase-activating proteins (RalGAPs). RalA and RalB regulate signal transduction pathways, cell division, cytoskeletal dynamics, vesicular transport, and cell migration. Ral GTPases are implicated in the pathogenesis of various cancers and are actively researched as potential therapeutic targets due to their role in tumor initiation, progression, and cancer stem cell function. Notably, they mediate EGFR/MAPK signaling, impact cellular shape through the JNK pathway, and orchestrate biological processes essential for tissue homeostasis and regeneration. While direct drug targeting is still under development, their activity serves as a biomarker and mechanistic focus in cancer research.

Other names
RalARalBRas-related protein Ral-ARas-related protein Ral-BDRal (Drosophila homolog)
02

Mechanism of action

Inhibiting Ral activation or disrupting its binding to downstream effectors (e.g., by modulating guanine nucleotide exchange factors or GTPase-activating proteins). Inhibiting Ral-GTP-dependent signaling can reduce tumor cell growth, migration, and invasion.

03

Biological functions

Signal transductionCell proliferationCell cycle progression (G1 to S phase)Cytoskeletal reorganizationVesicular transport and exocytosisCell migration and shape changesStem cell proliferation and regenerationTranscription regulationApoptosis
04

Disease associations

Cancer (liver, ovary, lung, brain, pancreatic ductal adenocarcinoma, nerve sheath tumors)Tumor initiation and progression
05

Safety considerations

Ral GTPases are widely expressed and involved in essential cell physiology, so their inhibition may impact normal cell function and tissue homeostasis (e.g., stem cell proliferation/regeneration, immune responses)Specific safety concerns related to direct inhibitors are yet to be fully elucidated due to the experimental status of therapies.
06

Interacting drugs

Aurora Kinase inhibitors

1 more in the full profile.

07

Biomarkers

Elevated RalA activity (especially in cancer stem cells compared to differentiated tumor cells)High Ral GTPase activity or altered RalGAP expression in certain cancers (e.g., pancreatic ductal adenocarcinoma)

Beyond the preview

Go deeper on Ras-related protein Ral (Ral GTPase (RalA, RalB)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ras-related protein Ral (Ral GTPase (RalA, RalB)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call